Ulrich Neumann, MBA MSc MA BSc BA, is the Founder and Managing Director at Pharmvivo Ventures, a strategic knowledge and networking platform for b2b exchanges in lifesciences. He also serves as Senior US Director at Certara, where he leads the Access and Commercial Strategy team in New York. Valued at over $5B, Certara is a drug development strategy and software startup listed on Nasdaq. With a dual background in business and public administration, Ulrich works on reimbursement and commercial strategy projects with pharma developers, while also serving as lead for commercial due diligences for private equity clients.
His commercial experience lies in defining product strategy, value messaging and b2b brand development. The founder of several entrepreneurial ventures, Ulrich most recently led the US division of a global pharma networking platform (now part of Thomson Reuters). He joined Certara in early 2017, having worked on go-to-market projects for over ten years, leading multimillion $ P&Ls and cross-functional academic/commercial teams in Europe and the US. Working in public and corporate affairs, he led strategy projects for multi-national clients in the health, bottled water, energy, and defense industries, serving placements at agencies such as Advice Partners and Hill & Knowlton (WPP), at the President of the EU Parliament as well as on projects funded by France’s Ministry of Foreign Affairs. A frequent expert contributor and conference speaker, Ulrich manages and hosts “The Market Access Radar”, a weekly Certara broadcast on current pharma policy and reimbursement topics.
Ulrich holds an MBA from Imperial College London, an MSc from the London School of Economics and an MA from the University of Southern California, Annenberg School and Marshall School of Business. His undergraduate degrees are in Public Administration (BSc) and Multi-level Governance (BA). The author of two books, he has published various trade articles, whitepapers, reports, and posters on critical pharma and managed care topics. Ulrich is frequently speaking at industry conferences and lectures, such as leading a graduate seminar on clinical trial innovation at Rutgers University Business School (Irvine Center). An active member of AMCP, AMBA, DIA and ISPOR, he is also a nominated Fellow of the Royal Society of Arts and Commerce since 2014.